Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Up 7.1% – Should You Buy?

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX)’s share price rose 7.1% during trading on Thursday . The stock traded as high as $0.2447 and last traded at $0.2420. Approximately 536,395 shares were traded during mid-day trading, an increase of 6% from the average daily volume of 503,976 shares. The stock had previously closed at $0.2260.

Theriva Biologics Stock Down 3.5%

The business’s 50 day moving average is $0.23 and its 200 day moving average is $0.25. The company has a market capitalization of $7.88 million, a price-to-earnings ratio of -0.01 and a beta of 1.14. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.13 and a current ratio of 1.13.

Theriva Biologics (NYSEAMERICAN:TOVX) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.07) earnings per share (EPS) for the quarter.

About Theriva Biologics

Theriva Biologics, Inc is a clinical-stage biotechnology company focused on developing treatments that use microbiome-based technologies and targeted biological approaches to address serious diseases. The company’s portfolio includes investigational therapies for oncology and gastrointestinal conditions.

Its lead oncology program, VCN-01, is a genetically modified oncolytic adenovirus designed to selectively replicate in tumor cells and stimulate an immune response against cancer. Theriva has studied VCN-01 in combination with chemotherapy for pancreatic ductal adenocarcinoma.